Reports Q3 revenue $1.105, consensus $1.07B. “IDEXX made exceptional progress on our innovation-driven growth strategy with strong execution and global customer adoption,” said Jay Mazelsky, President and CEO. “Building on the successful launch of IDEXX Cancer Dx, new Catalyst specialty tests for Pancreatic Lipase and Cortisol, and the transformative impact of IDEXX inVue Dx, we are delivering powerful new diagnostic capabilities. These solutions elevate clinical insights, streamline workflows, and create meaningful value for veterinary teams. The enthusiastic response – as reflected in our strong growth profile -highlights the trust our customers place in IDEXX.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- These Are the Stocks Reporting Earnings Today – November 3, 2025
- Is IDXX a Buy, Before Earnings?
- Apple upgraded, Comcast downgraded: Wall Street’s top analyst calls
- Idexx Laboratories upgraded to Buy from Hold at Stifel
- Idexx Laboratories’ Innovative Diagnostics Drive Buy Rating Amid Strong Growth Prospects